基因改造

US court deals blow over DNA patents

Companies cannot patent specific pieces of DNA, the US Supreme Court declared yesterday in a mixed decision that also affirmed the rights of the $83bn biotechnology industry in synthetic genetic products.

The justices ruled that synthetic DNA – strands of genetic material that have been modified in a lab – could be patented because this process involved some human input.

The court’s decision invalidated the patents that Myriad Genetics, a biotech company based in Utah, had registered on two human genes: BRCA1 and BRCA2.

您已閱讀35%(523字),剩餘65%(963字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×